HBMK — Hubei Minkang Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2009 March 31st | 2010 March 31st | 2011 March 31st | 2012 December 31st | 2013 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 13.9 | 14.7 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 6.76 | 6.29 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.118 | 1.75 | 0.715 | 12.8 | 14.5 |
Operating Profit | -0.118 | -1.75 | -0.715 | 1.15 | 0.222 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.199 | -1.83 | -0.769 | 0.955 | 0.073 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.199 | -1.83 | -0.769 | 0.961 | 0.127 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.199 | -1.83 | -0.769 | 0.961 | 0.127 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.199 | -1.83 | -0.769 | 0.961 | 0.127 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.029 | -0.023 | -0.016 | 0.02 | 0 |
Dividends per Share |